Additional Relevant Details Innoviva, the company formerly know as Theravance, repurchased approximately $37.3 million dollars through January 29, 2016.  Michael W. Aguiar, President and Chief Executive Officer of Innoviva called it a "commitment to generating long-term stockholder value".  The Company currently is in a $150 million share repurchase program through a combination of a "modified Dutch auction" tender offer (completed in December 2015) and open market purchases.